SLC post of interest: slcimmuno Member Level
Post# of 72447
(Total Views: 489)
Posted On: 05/17/2017 11:35:45 AM
SLC post of interest:
slcimmuno Member Level Tuesday, 05/16/17 07:35:04 PM
Re: DaubersUP post# 182150
Post # of 182371
More on Brilacidin / HDP-Ms for ABX
Though put on the back-burner for the time being, CTIX push w B IBD and B OM, hopefully B ABX one day share the spotlight. Pressure to get new drugs into patients is only going to increase.
//
"Antibiotics in late clinical development" (June 2017)
14 Defensin-mimetic peptides
Antibacterial peptides are innate antibacterial compounds found in human and animal tissues and cells, especially white cells. These peptides help in defending the body against bacterial infections. The first molecule that entered clinical development was magainin, which was derived from frog skin. However, this molecule dropped out of development due to manufacturing, stability, and potency issues. Many antibacterial peptides have been described since the discovery of the magainin peptide. Brilacidin (Cellceutix Corp/Polymedix/U.Penn) is a defensin-mimetic, non-peptidic molecule that was designed by chemists to mimic the amphiphilic properties of antimicrobial peptides and is being developed to treat ABSSSI. Brilacidin is bactericidal for Gram-positive and Gram-negative bacteria and is extraordinary in that it is also bactericidal even for non-replicating bacteria [49]. It targets the bacterial cell membrane and has been demonstrated to have low mammalian membrane disruptive properties along with low mammalian cell cytotoxicity. Two Phase 2 studies (NCT02052388) were completed successfully in 430 subjects with ABSSSI comparing three dosing regimens of brilacidin to daptomycin for the treatment of ABSSSI. All brilacidin treatment regimens were shown to be well tolerated.
[...]
"The arms race is, and will always be, an on-going battle with bacteria that are continuously evolving due to selective pressure to develop resistance to the antibiotic du jour. We can only hope to stay ahead with our pursuit of new antibiotics."
http://www.sciencedirect.com/science/article/...5216303082
slcimmuno Member Level Tuesday, 05/16/17 07:35:04 PM
Re: DaubersUP post# 182150
Post # of 182371
More on Brilacidin / HDP-Ms for ABX
Though put on the back-burner for the time being, CTIX push w B IBD and B OM, hopefully B ABX one day share the spotlight. Pressure to get new drugs into patients is only going to increase.
//
"Antibiotics in late clinical development" (June 2017)
14 Defensin-mimetic peptides
Antibacterial peptides are innate antibacterial compounds found in human and animal tissues and cells, especially white cells. These peptides help in defending the body against bacterial infections. The first molecule that entered clinical development was magainin, which was derived from frog skin. However, this molecule dropped out of development due to manufacturing, stability, and potency issues. Many antibacterial peptides have been described since the discovery of the magainin peptide. Brilacidin (Cellceutix Corp/Polymedix/U.Penn) is a defensin-mimetic, non-peptidic molecule that was designed by chemists to mimic the amphiphilic properties of antimicrobial peptides and is being developed to treat ABSSSI. Brilacidin is bactericidal for Gram-positive and Gram-negative bacteria and is extraordinary in that it is also bactericidal even for non-replicating bacteria [49]. It targets the bacterial cell membrane and has been demonstrated to have low mammalian membrane disruptive properties along with low mammalian cell cytotoxicity. Two Phase 2 studies (NCT02052388) were completed successfully in 430 subjects with ABSSSI comparing three dosing regimens of brilacidin to daptomycin for the treatment of ABSSSI. All brilacidin treatment regimens were shown to be well tolerated.
[...]
"The arms race is, and will always be, an on-going battle with bacteria that are continuously evolving due to selective pressure to develop resistance to the antibiotic du jour. We can only hope to stay ahead with our pursuit of new antibiotics."
http://www.sciencedirect.com/science/article/...5216303082
(1)
(0)